Treating HER2-Positive Metastatic Breast Cancer: DESTINY-Breast02 and DESTINY-Breast03

Video

The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.

The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.

Related Videos
Dr. Manisha Thakuria in an interview with CURE
Dr. Beth Goldstein in an interview with CURE
D'Agostino in an interview with CURE
Dr. Chapman-Davis in an interview with CURE
Dr. Psutka in an interview with CURE
Dr. Nitin Ohri in an interview with CURE
Dr. Ngwa in an interview with CURE
Dr. Claudia DeYoung in an interview with CURE
Dr. Toni Choueiri in an interview with CURE at the 2023 KCRS
Related Content